FDA Approves Gilead's Long-Acting HIV Treatment for Bi-Monthly Dosing
Gilead's long-acting HIV treatment has received FDA approval for bi-monthly dosing, providing patients with a more convenient and effective management option.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: March 31, 2026
The U.S. Food and Drug Administration (FDA) has granted approval to lenacapavir (Sunlenca), Gilead Sciences' first-in-class capsid inhibitor, for bi-monthly treatment of HIV-1 infection in heavily treatment-experienced adults. The approval, announced on December 22, 2023, marks a significant advancement in HIV treatment, offering a novel twice-per-year dosing option for patients with limited treatment alternatives.
Breakthrough Long-Acting Treatment Option
Lenacapavir represents the first HIV-1 capsid inhibitor and introduces an innovative mechanism of action in the fight against HIV. The drug works by interfering with multiple stages of the viral lifecycle, offering a new approach for patients who have developed resistance to other antiretroviral therapies.
Clinical Evidence Supporting Approval
The FDA's decision was based on data from the pivotal CAPELLA trial (NCT04150068), which demonstrated significant efficacy in heavily treatment-experienced people living with multi-drug resistant HIV-1. At week 52, 83% of participants (n=36) receiving lenacapavir in combination with an optimized background regimen achieved viral suppression (HIV-1 RNA <50 copies/mL).
Key efficacy data included:
- Viral load reduction: -1.94 log10 copies/mL (p<0.0001)
- CD4+ count increase: median 81 cells/µL
- Treatment response rate: 81% at 26 weeks
Safety Profile and Administration
The most common adverse reactions (≥3%) included injection site reactions (63%), nausea (4%), and fatigue (3%). The bi-monthly dosing schedule begins with oral loading doses on days 1 and 2, followed by subcutaneous injections on day 8 and every 26 weeks thereafter.
Market Impact and Access
Gilead Sciences plans to launch lenacapavir in January 2024, with a wholesale acquisition cost of $42,250 per year. The company has announced comprehensive patient support programs to help ensure access to the medication.
Expert Commentary
"The approval of lenacapavir represents a significant innovation in HIV treatment," said Dr. Deborah Birnkrant, director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research. "Its unique mechanism of action and twice-yearly dosing schedule could be transformative for patients with limited treatment options."
Frequently Asked Questions
What makes lenacapavir different from other HIV treatments?
Lenacapavir is the first HIV capsid inhibitor and offers bi-monthly dosing, compared to daily oral medications typically used in HIV treatment.
Who is eligible for lenacapavir treatment?
The drug is approved for adults with multi-drug resistant HIV-1 infection whose current antiretroviral regimen is failing.
When will lenacapavir be available?
Gilead Sciences plans to make lenacapavir available in the United States in January 2024.
Looking Ahead: Gilead is conducting additional studies of lenacapavir in broader HIV-1 patient populations, including the SUNRISE and SUMMIT trials investigating its potential as a pre-exposure prophylaxis (PrEP) option.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
